VedaBio, a groundbreaking biotechnology firm specializing in molecular detection, has announced a non-exclusive licensing agreement with Mammoth Biosciences, Inc. This partnership will enable VedaBio to utilize select CRISPR-based technologies in diagnostic applications. “We’re thrilled to work with the Mammoth team to help bring the full promise of CRISPR-based diagnostics to market,” said Frederic Sweeney, PhD, President and CEO of VedaBio. The agreement grants VedaBio access to essential CRISPR intellectual property, which will accelerate the development of tailored diagnostic solutions. This collaboration underscores VedaBio’s dedication to building an advanced platform aimed at speed and precision, particularly in decentralized healthcare environments. “This initiative expands the avenues for our proprietary platform and allows us to develop highly targeted, amplification-free molecular tests designed for real-world clinical needs,” added Sweeney. Janice Chen, PhD, Co-founder and CTO of Mammoth Biosciences, remarked, “Mammoth’s vision for diagnostics is to enable new solutions that have high impact on patient care. The combination of Mammoth’s deep CRISPR intellectual property with VedaBio’s unique approach and product vision is an opportunity to deliver on the potential of CRISPR-based diagnostics.” The integration of CRISPR-based detection allows for precise molecular recognition, facilitating rapid and accurate diagnostics that can be deployed in urgent care, outpatient clinics, and other decentralized settings while maintaining sensitivity and specificity. With this collaboration, VedaBio is poised to spearhead the next generation of CRISPR-powered diagnostics, offering solutions that are quicker, more cost-effective, and closely aligned with the current healthcare landscape. About VedaBio VedaBio is leading the charge in molecular detection, leveraging cutting-edge CRISPR technology to provide fast, accurate, and accessible diagnostics. The company is committed to advancing the next generation of molecular diagnostics to enhance healthcare outcomes globally. About Mammoth Biosciences Mammoth Biosciences is focused on utilizing its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients facing life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna along with Trevor Martin, Janice Chen, and Lucas Harrington, the company’s systems are designed to be more specific and facilitate in vivo gene editing in challenging tissues. Mammoth is expanding its pipeline of potential in vivo gene editing therapeutics and has formed partnerships with leading pharmaceutical and biotechnology firms to enhance the reach of its innovative technology platform. For further details, visit vedabio.com and mammoth.bio.